Von Willebrand Disease, Type 3
Hematology·MeSH: von Willebrand Disease, Type 3
Prevalence
30.0 / 100K
2 drugs in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 3(1)
Phase 4(1)
| Drug | Company |
|---|---|
| Emicizumab | ENANTA PHARMACEUTICALS INC (ENTA) |
Compare drugs
Frequently asked questions
How many drugs are in development for Von Willebrand Disease, Type 3?
BioSniper tracks 2 drugs in development for Von Willebrand Disease, Type 3 across 1 company.
How many clinical trials target Von Willebrand Disease, Type 3?
There are 2 clinical trials targeting Von Willebrand Disease, Type 3 tracked by BioSniper.
What is the prevalence of Von Willebrand Disease, Type 3?
The estimated prevalence of Von Willebrand Disease, Type 3 is approximately 30.0 per 100,000 population.
Deep-dive into Von Willebrand Disease, Type 3
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis